| Cancer care has been undergoing a revolution where it is becoming more personalised, moving from a one drug fits all model, to the identification of one patient group by companion diagnostics and where one biomarker is associated with one drug. In the future, utilization of massively-parallel sequencing (i.e., next-generation sequencing [NGS]) together with electronic medical records (eMRs) would greatly facilitate collection and analysis of real world clinical data to inform clinical development programs of pharmaceutical companies and decision making of oncologists. As more targeted therapies become available, we will be able to individualise each patient’s cancer care and treatment strategy based on his or her tumor profile. In this presentation, some real-world experience and challenges of clinical utilities of NGS will be discussed. |
